Net sales grew 34% in Q2 2026, driven by strong Thoracic and Abdominal segment growth, while Services declined. EBITDA margin improved to 19%, and positive clinical trial results and regulatory progress support a strong outlook for continued expansion.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.